StreetInsider.com News Articles

Form 4 Ginkgo Bioworks Holdings For: May 21 Filed by: Coen Steven P.

Tue, 26 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260526/26551132.html

Form 4 Ginkgo Bioworks Holdings For: May 21 Filed by: Coen Steven P.

Tue, 26 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260526/26551132.html

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Tue, 26 May 2026 12:33:00 -0400

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification

BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One^™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Tue, 26 May 2026 12:33:00 -0400

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Tue, 26 May 2026 12:33:00 -0400

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Tue, 26 May 2026 12:33:00 -0400

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Fri, 22 May 2026 15:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26541187.html

Form 144 Ginkgo Bioworks Holdings Filed by: Coen Steven P.

Fri, 22 May 2026 15:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26541187.html

Form SCHEDULE 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260515/26508120.html

Form SCHEDULE 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP

Fri, 15 May 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260515/26508120.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Wed, 13 May 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260513/26483720.html

Form 144 Ginkgo Bioworks Holdings Filed by: Che Austin

Wed, 13 May 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260513/26483720.html

Ginkgo Bioworks (DNA) Misses Q1 EPS by 128c

Thu, 07 May 2026 16:50:02 -0400

Ginkgo Bioworks (NYSE: DNA) reported Q1 EPS of ($1.28). Revenue for the quarter came in at $19.47 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.

Form 10-Q Ginkgo Bioworks Holdings For: Mar 31

Thu, 07 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260507/26453557.html

Form 10-Q Ginkgo Bioworks Holdings For: Mar 31

Thu, 07 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260507/26453557.html

Form 8-K Ginkgo Bioworks Holdings For: May 07

Thu, 07 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26453233.html

Form 8-K Ginkgo Bioworks Holdings For: May 07

Thu, 07 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26453233.html

Ginkgo Bioworks reports Q1 2026 revenue decline after biosecurity sale

Thu, 07 May 2026 16:05:33 -0400

Ginkgo Bioworks Holdings Inc. (NYSE: DNA) reported first quarter 2026 revenue of $19 million, down 49% from $38 million in the prior year period, according to the company's financial results released Tuesday.

The biotechnology company completed the divestiture of its Biosecurity business on April 3, 2026, and now presents those operations as discontinued operations in its financial statements. Excluding a $7 million non-cash deferred revenue release in the first quarter of 2025, revenue declined 37% from $31 million in the comparable period.

Ginkgo reported a GAAP net loss from continuing operations of $76 million for the quarter, compared to $83 million in

Ginkgo Bioworks reports Q1 2026 revenue decline after biosecurity sale

Thu, 07 May 2026 16:05:33 -0400

Ginkgo reported a GAAP net loss from continuing operations of $76 million for the quarter, compared to $83 million in

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Thu, 07 May 2026 16:05:00 -0400

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Thu, 07 May 2026 16:05:00 -0400

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Thu, 07 May 2026 16:05:00 -0400

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Thu, 07 May 2026 16:05:00 -0400

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

AWS Taps Ginkgo Bioworks, Twist Bioscience for New "Amazon Bio Discovery" Platform

Thu, 07 May 2026 14:08:16 -0400

AWS Taps Ginkgo Bioworks (NYSE: DNA), Twist Bioscience (NASDAQ: TWST) for New "Amazon Bio Discovery" Platform

AWS has launched Amazon Bio Discovery, a new application that integrates 40+ AI biological foundation models with a physical lab network to slash antibody design time from years to weeks.
Ginkgo Bioworks (DNA) and Twist Bioscience (TWST) are featured as inaugural integrated lab partners, allowing researchers to transition from AI-generated designs to physical synthesis and testing with a few clicks

AWS Taps Ginkgo Bioworks, Twist Bioscience for New "Amazon Bio Discovery" Platform

Thu, 07 May 2026 14:08:16 -0400

AWS Taps Ginkgo Bioworks (NYSE: DNA), Twist Bioscience (NASDAQ: TWST) for New "Amazon Bio Discovery" Platform

AWS has launched Amazon Bio Discovery, a new application that integrates 40+ AI biological foundation models with a physical lab network to slash antibody design time from years to weeks.
Ginkgo Bioworks (DNA) and Twist Bioscience (TWST) are featured as inaugural integrated lab partners, allowing researchers to transition from AI-generated designs to physical synthesis and testing with a few clicks